Clinical characteristics of the final study cohort are shown in Table 1.
The final study cohort was comprised of 21,771 individuals, including 9282 CD and 12,489 UC patients (Fig. 1).
As only the first episode was eligible for analysis in patients with multiple episodes of HH during the study period, the final study cohort comprised 1116 patients.
From the 433 patients who had an MSCT-CA, 20 (5%) were lost to follow-up, resulting in a final study cohort of 413 individuals.
The final study cohort comprised 420 095 private mobile phone subscribers.
This method of elimination resulted in a final study cohort of 725 non-diabetic individuals.
As outlined in Figure 1, 1291 (60%) participants did not meet the inclusion criteria, resulting in a final study cohort of 858 subjects.
Our final study cohort comprised 734 899 women.
The final study cohort consisted of 1083 patients.
The final study cohort comprised of 391 patients.
The final study cohort comprised 681,104 subjects (Fig. 1).
